<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1241">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05144997</url>
  </required_header>
  <id_info>
    <org_study_id>B7461039</org_study_id>
    <secondary_id>2021-005569-42</secondary_id>
    <nct_id>NCT05144997</nct_id>
  </id_info>
  <brief_title>Lorlatinib Continuation Study</brief_title>
  <official_title>LORLATINIB (PF-06463922) CONTINUATION PROTOCOL: AN OPEN-LABEL, SINGLE-ARM CONTINUATION STUDY FOR PARTICIPANTS WITH ALK-POSITIVE OR ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) CONTINUING FROM PFIZER SPONSORED LORLATINIB CLINICAL STUDIES</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this protocol is to provide continued treatment access and safety follow-up&#xD;
      for eligible participants who continue to derive a benefit from study intervention in the&#xD;
      Pfizer sponsored lorlatinib parent studies that will be closed. Additional follow-up safety&#xD;
      data collection will permit further characterization of the safety profile of lorlatinib in&#xD;
      participants continuing to receive study intervention&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 31, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2026</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events leading to permanent discontinuation of study intervention</measure>
    <time_frame>Baseline up to approximately 5 years</time_frame>
    <description>Safety collection in this study will permit further characterization of the safety profile of lorlatinib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of serious adverse events reported for all participants</measure>
    <time_frame>Baseline up to approximately 5 years</time_frame>
    <description>Safety collection in this study will permit further characterization of the safety profile of lorlatinib</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Non-Small-Cell Lung Cancer</condition>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>Lorlatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lorlatinib single agent, 100 mg (4 x 25 mg) oral tables, QD, continuously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lorlatinib</intervention_name>
    <description>ALK-positive NSCL treatment</description>
    <arm_group_label>Lorlatinib</arm_group_label>
    <other_name>PF-06463922</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1 - Any participant who is receiving study treatment and deriving clinical benefit (as&#xD;
        determined by the Principal Investigator) in a Pfizer-sponsored Lorlatinib Parent Study&#xD;
        with no ongoing NCI CTCAE Grade â‰¥3 or intolerable Grade 2 AEs considered to be related to&#xD;
        lorlatinib treatment.&#xD;
&#xD;
        2- Participants must agree to follow the reproductive criteria. 3- Adequate Bone Marrow,&#xD;
        Liver, Renal, Pancreatic Function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1 - Female participants who are pregnant or breastfeeding. 2- Any medical reason that, in&#xD;
        the opinion of the Investigator or Sponsor, precludes the participant from inclusion in the&#xD;
        study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B7461039</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 22, 2021</study_first_submitted>
  <study_first_submitted_qc>November 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2021</study_first_posted>
  <last_update_submitted>November 22, 2021</last_update_submitted>
  <last_update_submitted_qc>November 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALK</keyword>
  <keyword>anaplastic lymphoma kinase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

